ClinicalTrials.gg
RecruitingNCT07602166Updated Nov 4, 2026

Effect of an Isolevuglandin Scavenger on Salt Sensitivity of Blood Pressure and Immune Cell Activation in Humans

A Phase 2 interventional study of 2-hydroxybenzylamine and Placebo in Salt Sensitivity of Blood Pressure, High Blood Pressure and Inflammation, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Vanderbilt University Medical Center · Phase 2, Interventional, and Treatment

How we know

Updated Nov 4, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Hypertension by Vanderbilt University Medical Center — 8 open to participants now, 8 under way, none of them phase 3. Hypertension · Vanderbilt University Medical Center.

Planned enrollment
10th of 19
20 · median 20
Started
2026
with 1 other
Phase 2
4 of 23
2 open now
Registered
23rd of 23
by date

Among the 23 studies in Hypertension by Vanderbilt University Medical Center, this one is the 10th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2026, is one of 4 in phase 2, and was the 23rd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

8 of the 23 studies in Hypertension by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Hypertension by Vanderbilt University Medical Center, or all of them as a file.
02

Study summary

Hypertension is the leading cause of preventable deaths globally, driven by complications such as myocardial infarction, stroke, heart failure, and kidney disease. Recent updates in hypertension classification by the American Heart Association (AHA) place nearly half of the U.S. population in the hypertensive category. Excess dietary salt is a major risk factor for hypertension, with 50% of hypertensive individuals exhibiting salt-sensitivity of blood pressure (SSBP). SSBP is an independent predictor of cardiovascular events and death. While kidney mechanisms in salt-sensing have been extensively studied, emerging evidence suggests that immune cells can also sense sodium (Na+).

This trial hypothesizes that myeloid cell-derived isolevuglandins (IsoLGs) drive endothelial dysfunction, perpetuating the salt-sensitive phenotype. Preliminary data indicate that targeting IsoLGs with the IsoLG scavenger 2-hydroxybenzylamine (2-HOBA) may interrupt this immune-vascular axis, reducing salt sensitivity and associated cardiovascular risks.

This phase 2 clinical trial aims to investigate the role of 2-HOBA in modulating immune cell function within blood vessels in hypertensive patients. The study will explore the impact of immunity on salt sensitivity and assess 2-HOBA's potential to reduce endothelial dysfunction, improve immune cell activation, and alleviate SSBP.

Read the detailed description

Investigators will perform a 12-week randomized, double-blind, placebo-controlled, 2x2 crossover proof-of-concept phase II study with treatment of 2-HOBA in participants previously phenotyped for SSBP. Investigators will randomize people with known SSBP (i.e., 10 mmHg drop in systolic blood pressure from salt-loading to salt-depletion) to treatment with 2-HOBA (500mg) three times a day for 4 weeks, followed by a washout period of 4 weeks, and then placebo for 4 weeks versus placebo then washout then 2-HOBA. Assessments will be obtained at week 0, 4, 8 and 12 per cross-over design above. The investigators will employ the Weinberger protocol in 20 patients as previously reported. Investigators will advise participants to maintain their usual diet and salt consumption until the onset of the protocol and provide the participant with a container and appropriate instructions to collect a 24-hour urine specimen the day before admission to the hospital. Admission will take place two weeks later, for washout of the effect of the medications, and on an evening, for the patient to rest overnight in the hospital before onset on the protocol. During these two weeks, untreated blood pressure will be monitored either by the patients at home or in interim scheduled visits, to assure that it does not exceed 180/110 mmHg, in which case the protocol will be discontinued for safety. On admission, volume of the baseline urine will be measured, and aliquots sent to the lab or frozen at -80ºC for research analytes. On the morning after admission (6 am) an ambulatory blood pressure monitor (SpaceLabs 90207 or 90210) will be set up for continuous blood pressure recording throughout the study (every 15 minutes from 6 am until 10 pm and every 30 minutes from 10 pm to 6 am), body weight will be recorded with the patient wearing a gown (same scale as future days), blood samples will be obtained for the analytes of the study described below (baseline tests), and a new 24-hour collection will be started for the period of salt loading at 8 am. Salt loading will be achieved by the combination of a high-salt diet (isocaloric, with 160 mEq Na and 70 mEq K), which the patient will consume in its entirety, and an infusion of 2L of saline (300 mEq Na+). Patients will have free access to water but their food will be limited to that provided by the protocol. Participants will retire to bed at 10 pm. On the following morning (6 am) body weight and blood samples will again be obtained, and the 24-hr collection will be completed with an intentional voiding at 8 am. These laboratory data will reflect the effect of salt loading. At 8 am, subjects will be subjected to salt depletion. This is accomplished by administering an isocaloric diet containing 10 mEq Na and 70 mEq K and continued unlimited water intake. At 8 am, 12 noon and 4 pm, subjects will be given 40 mg of furosemide orally. An additional 12-hour urine collection will be started at 8 am and ended with an intentional void at 8 pm (reflecting the period of furosemide natriuresis). A new 12-hour collection will start at 8 pm, to be closed with intentional voiding the next morning at 8 am (reflecting the period of salt depletion). The next morning (6 am) the last recording of body weight and drawing of blood samples will take place, and by 8 am the 12-hour urine collection for the period of salt depletion will be completed. The patients will be given breakfast from a regular hospital diet, which may be supplemented with salty food or fluids if the salt depletion intervention produced dizziness or documented orthostasis. Once the patient is stable and exhibits tolerance to the upright posture, the participant will be discharged home with instructions to resume antihypertensive medications, unless the presence of orthostasis requires a modification in the regimen, which will be advised by a physician member of the research team. Laboratory blood measurements: Tests to be conducted in the 3 daily sets of blood samples will include CBCs and CMP at the central laboratory of VUMC. Mass spectrometry will be performed at baseline, after salt-loading and depletion to confirm if SSBP is associated with IsoLG-adducts in isolated human monocytes and plasma by Core B. Isolated monocytes and plasma fractions will be immediately stored at -80ºC upon collection until analyzed by mass spectrometry as previously described.25 Serum and urine creatinine, Na+ and K+ will be analyzed at the central laboratory of Vanderbilt. Plasma renin activity and aldosterone will be measured by radioimmunoassay. Plasma and urine eicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE) will be measured at the Vanderbilt eicosanoid core by liquid chromatography/tandem mass spectrometry. Assessing activity of the renin-angiotensin-aldosterone system and eicosanoids is part of the usual phenotyping of SS and SR subjects. Tests to be conducted in the 4 urine specimens (24-hr baseline, 24-hr salt loading, 12-hr furosemide natriuresis, and 12-hr salt depletion) will include: urinalysis, Na+, K+, and creatinine concentration at the central laboratory of VUMC; urine eicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE) at the eicosanoid core of VUMC by liquid chromatography/tandem mass spectrometry. Urine pregnancy tests will be performed in women of childbearing potential. Definition of salt sensitivity of blood pressure: Blood pressure data from the monitors will be downloaded and the average of the systolic blood pressure of the day of salt loading, from 12 noon (end of the saline infusion) until 10 pm will be used as the BP for the salt-loading period of study. The average of the systolic blood pressure of the day of salt depletion, from 12 noon (second dose of furosemide) until 10 pm will be used as the BP for the salt-depleted period of study. A fall in systolic BP ≥10 mm Hg from the salt-loading to the salt-depletion periods will be used to classify a subject as salt sensitive. Immune Cell Activation Studies: The investigators will determine if salt sensitivity is associated with the activation state of human monocytes. Heparinized blood samples (40 ml) are obtained and PBMCs are isolated by Ficoll-gradient. Monocytes are isolated from the PBMC by magnetic labeling and negative selection using the Miltenyi monocyte isolation kit and analyzed using flow cytometry. Investigators will identify monocytes as CD45+/CD14+ cells and can further examine intermediate (CD14+/CD16+ and non-classical monocytes (CD14-/CD16+). The CD14+/CD16+ cells which comprise about 10% of the circulation, are of particular interest they produce increased levels of TNFalpha and promote T cell activation. These are increased in humans with hypertension and in response to in vitro elevated Na+ exposure. Although subtypes of DCs are relatively rare in number, the investigators will quantify them by measuring CD45+/CD1c+, CD45+/CD141+, CD45+/CD209+, CD45+/CD83+ and the recently identified Axl/SICLEC6 cells. 7-AAD is used to exclude dead cells. Intracellular staining with the single chain antibody D-11 to detect IsoLG-protein adducts will be used. Surface expression of CD80 and CD86, which are expressed on mature antigen-presenting cells allowing them to participate in T cell co-stimulation will be measured. General characterization of peripheral blood mononuclear cells by flow cytometry for other inflammatory cells including total leukocytes (CD45+ cells), B cells (CD45+/CD19+), total T cells (CD45+/CD3+ cells), and the T cell subtype (CD3+/CD8+ and CD4+) cells will also be performed. These experiments will be performed in freshly-isolated cells and also in monocytes exposed to normal salt or high salt for 48 hours to determine if salt-sensitivity is reflected in the monocytes. Medium from monocytes cultured for 48 hours is analyzed for cytokine release including IL-1 beta, TNF-alpha, IL-6, and IL-23 using luminex. The investigators will also obtain plasma to assess for cytokines including GM-CSF, IL-4, and Flt3 lig and that are responsible for conversion of monocytes to DCs. To ensure reproducibility, the samples will be submitted to the Vanderbilt Endocrinology and Metabolism Core Facility to perform a blinded Luminex analysis. Measurements of O2·- production and activation of NADPH oxidase including phosphorylation of p47phox and association of p47phox with gp91phox by immunoprecipitation and western blot both at baseline and in response elevated Na+ will be done previously described.Flow mediated vasodilatation (FMD) procedure: For Aim 2, Investigators will perform FMD studies with co-investigator Dr. Shibao, following published guidelines.30,31 Briefly, the brachial artery diameter will be measured using B-mode ultrasonography equipped with a high-resolution linear array transducer (10-14 mHz). A longitudinal image (parallel to the artery), proximal to the antecubital fossa will be obtained with the transducer positioned to optimize images of the near and far wall interfaces. A simultaneous ECG signal is recorded, and images are digitally acquired at end-diastole, synchronized to the R wave on the ECG. To assess endothelium-dependent vasodilation, brachial artery diameter will be measured under basal conditions and during reactive hyperemia. Reactive hyperemia results from a five-minute vascular occlusion produced by rapidly (0.3 seconds) inflating a blood pressure cuff placed distal to the imaging site up to supra-systolic pressures (200-250 mm Hg). Following cuff deflation, the maximal increase in brachial artery diameter occurs at approximately 1 minute of reactive hyperemia, a response mediated by endothelium-derived nitric oxide. Additionally, Investigators will determine the true peak diameter on an individual basis and will report the peak vasodilation. After a rest period to reestablish basal conditions, endothelium-independent vasodilation will be assessed by imaging the brachial artery under basal conditions and following the administration of sublingual nitroglycerin (0.4 mg). The half-life of nitroglycerin is three minutes; however, its effects on the vasculature could last for up to 30 minutes; therefore, Investigators will delay performing any measurements or procedure during this period. The video output and electrocardiographic signal of the ultrasound machine is connected to a computer equipped with a Data Translation frame grabber video card. The R wave on the electrocardiogram is used as a trigger to acquire (digitize) frames. Digitized images at baseline and after intervention (e.g., reactive hyperemia, nitroglycerin) will be stored on the hard drive and backed up on removable media. Acquisition and analysis of the stored images is performed using software designed for this purpose by Medical Imaging Applications as previously published by our group. 32 The vessel wall lumen interface is determined by derivative based edge detection following the identification of the region of the anterior and posterior walls by the investigator. The maximum diameter of the vessel is determined and the percent change in diameter (% vasodilation) can be calculated. Endothelial Cell Harvesting and Analysis: This procedure will be performed in the contralateral arm of the FMD, and before FMD. Investigators will harvest endothelial cells using 4 sterile J-wires. The J-wires will be briefly advanced (\~5 cm beyond the tip of the catheter) and retracted through an 18-gauge catheter. The wires will be transferred to a dissociation buffer solution and washed 10 times to detach the endothelial cells. Harvested endothelial cells will undergo surface staining using markers: Live/Dead, CD45+, CD31+, CD54+, and CD144+. The cells will then be fixed, permeabilized and intracellular staining will be performed using D-11 for IsoLG formation and with anti-3-nitrotyrosine. Endothelial cells will be characterized by CD31+ CD45- expression using flow cytometry. Investigators will use fluorescence minus one (FMOs) and isotype controls to accurately adjust gates for all fluorophores.

03

Conditions studied

  • Salt Sensitivity of Blood Pressure
  • High Blood Pressure
  • Inflammation
  • Renin-Angiotensin-Aldosterone System

Keywords

  • salt sensitivity
  • hypertension
  • renin-angiotensin-aldosterone system
  • immune cells
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • We will perform analyses in participants previously phenotyped for SSBP, defined as a change in systolic blood pressure ≥10 mmHg from salt-loading to salt-depletion,
  • Over 18 years of age. Able to give ,

Exclusion criteria

Exclusion criteria:

  • Salt-resistant people,
  • Acute cardiovascular event(s) within the previous 6 months,
  • inability to understand the nature, scope, and possible consequences of the study or to participate in/comply with the protocol,
  • Current excessive alcohol or illicit drug use,
  • BP below the inclusion criteria levels after discontinuation of therapy,
  • Concomitant diabetes mellitus, type I or II,
  • disease,
  • Recent vaccination,
  • Younger or older than inclusion criteria,
  • Pregnant or breastfeeding
  • Women of unwilling to use highly effective (see Risk section),
  • Confirmed or suspected renal, renovascular or endocrine causes of secondary hypertension,
  • Treatment with agents known to increase BP (e.g., adrenergic agonists for ADHD, SSRI and SNRI antidepressants, chronic use of decongestants or non-steroidal anti-inflammatory drugs,
  • Active or ongoing infection, including /AIDS,
  • Active or ongoing with the exception of basal cell carcinoma of the skin,
  • Severe psychiatric disorders,
  • Any condition that may alter the immunological results of the study including rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, giant cell arteritis, psoriasis, inflammatory bowel disease, and multiple sclerosis,
  • Use of , , direct immunomodulators or chemotherapeutic drugs that in the judgment of the investigators may include a major inflammatory component,
  • Individuals who have to high salt diets (e.g. heart, renal, or liver failure) or low salt diets (e.g. postural orthostatic tachycardia syndrome, prescribed salt tablets, fludrocortisone or midodrine) or 24-hr ambulatory blood pressure monitoring (e.g. women with bilateral upper extremity lymphedema following breast cancer surgeries),
  • Prior diagnosis of liver cirrhosis or the following abnormal liver function studies: or ALT >1.5x the or total ≥1.5 mg/dl,
  • Use of Aspirin,
  • Use of monoamine oxidase inhibitors (MAO-I),
  • Individuals with medical contraindications to certain food content,
  • Use of nitrate therapy. (Participants who are taking PDE-5 inhibitors will be instructed to discontinue use at least 48 hours prior to testing),
  • Patients with resistant hypertension, defined as above-goal blood pressure despite the concurrent use of three antihypertensive drug classes at screening, will be excluded for safety reasons,
  • Average of three office-based blood pressure readings greater than 160 mmHg systolic or 100 mmHg diastolic will not be eligible for enrollment,
  • Use of drugs such as anticoagulants (e.g., warfarin), beta-blockers, antiarrhythmics, antidepressants/antipsychotics, and other medications primarily metabolized by CYP2C9, CYP2C19, and CYP2D6 that may cause drug-drug interaction.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Arm 1: Drug-washout-placebo

    Participants with salt sensitivity of blood pressure to receive treatment with 2-HOBA (500mg) three times a day for 4 weeks, followed by a washout period of 4 weeks, and then placebo for 4 weeks

    Drug: 2-hydroxybenzylamine · Drug: Placebo

  • Experimental
    Arm 2: Placebo-washout-Drug

    Participants with salt sensitivity of blood pressure to receive treatment with placebo for 4 weeks followed by a washout period of 4 weeks, and then 2-HOBA (500mg) three times a day for 4 weeks.

    Drug: 2-hydroxybenzylamine · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in 24-hour ambulatory systolic blood pressure (SBP)

    Measurement of salt sensitivity of blood pressure before and after each treatment period (2-HOBA and placebo), using a standardized inpatient salt-loading and salt-depletion protocol.

    Time frame: From week 0-4 and week 8-week12

Secondary outcomes

  1. FMD

    Measurement of endothelial function using flow-mediated vasodilation (FMD)

    Time frame: From baseline to week 4, from Week 8 to week 12.

  2. Measurement of oxidative stress and inflammatory cytokines in blood and endothelial cells

    IL-1, IL-6 and IL-23 analysis using a Luminex-based assay. Assess for cytokines GM-CSF, IL-4, and Flt3 ligand.

    Time frame: Week 0, 4, 8 and 12.

  3. Endothelial Cell Harvesting and Analysis

    Assessment of IsoLG-adducts and inflammatory markers in harvested endothelial cells and immune cells.

    Time frame: From week 0-4 and week 8-12

07

Study locations

1 of 1 sites recruiting
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Recruiting
    • Annet Kirabo, D.V.M., M.Sc., Ph.D. F.A.H.A. · Contactannet.kirabo@vumc.org · 615-343-0933
    • Talat A Ikizler, MD · Contactalp.ikizler@vumc.org
    • Annet Kirabo, D.V.M., M.Sc., Ph.D. F.A.H.A. · Principal investigator
    • Talat A Ikizler, MD · Sub investigator
    • David Harrison, MD · Sub investigator
08

References and documents

Publications

  • Weinberger MH. Salt sensitivity is associated with an increased mortality in both normal and hypertensive humans. J Clin Hypertens (Greenwich). 2002 Jul-Aug;4(4):274-6. doi: 10.1111/j.1524-6175.2002.00924.x. PubMed 12147930 ↗
  • Ertuglu LA, Pitzer Mutchler A, Jamison S, Laffer CL, Elijovich F, Saleem M, Blackwell DJ, Kryshtal DO, Egly CL, Sahinoz M, Sheng Q, Wanjalla CN, Pakala S, Yu J, Gutierrez OM, Kleyman TR, Knollmann BC, Ikizler TA, Kirabo A. Eicosanoid-Regulated Myeloid ENaC and Isolevuglandin Formation in Human Salt-Sensitive Hypertension. Hypertension. 2024 Mar;81(3):516-529. doi: 10.1161/HYPERTENSIONAHA.123.21285. Epub 2023 Sep 7. PubMed 37675576 ↗
  • Weinberger MH. Salt sensitive human hypertension. Endocr Res. 1991;17(1-2):43-51. doi: 10.1080/07435809109027188. PubMed 1879381 ↗
  • Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension. 2001 Feb;37(2 Pt 2):429-32. doi: 10.1161/01.hyp.37.2.429. PubMed 11230313 ↗
  • Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension. 1986 Jun;8(6 Pt 2):II127-34. doi: 10.1161/01.hyp.8.6_pt_2.ii127. PubMed 3522418 ↗
  • Luft FC, Miller JZ, Grim CE, Fineberg NS, Christian JC, Daugherty SA, Weinberger MH. Salt sensitivity and resistance of blood pressure. Age and race as factors in physiological responses. Hypertension. 1991 Jan;17(1 Suppl):I102-8. doi: 10.1161/01.hyp.17.1_suppl.i102. PubMed 1846122 ↗
  • Weinberger MH, Fineberg NS. Sodium and volume sensitivity of blood pressure. Age and pressure change over time. Hypertension. 1991 Jul;18(1):67-71. doi: 10.1161/01.hyp.18.1.67. PubMed 1860713 ↗
  • Ertuglu LA, Demirci M, Mutchler AL, Laffer CL, Saleem M, Ikizler TA, Kirabo A. Antigen-Presenting Cell Isolevuglandins Link Salt Sensitivity of Blood Pressure to Insulin Resistance. J Clin Endocrinol Metab. 2026 Mar 17;111(4):1091-1097. doi: 10.1210/clinem/dgaf556. PubMed 41052782 ↗
  • Ertuglu LA, Pitzer Mutchler A, Elijovich F, Laffer CL, Sheng Q, Wanjalla CN, Kirabo A. Regulation of human salt-sensitivite hypertension by myeloid cell renin-angiotensin-aldosterone system. Front Physiol. 2023 Jul 18;14:1208270. doi: 10.3389/fphys.2023.1208270. eCollection 2023. PubMed 37534363 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jul 2031, 57 months after the start.

Of 54 non-industry phase 2 interventional studies under Hypertension, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 57 months is close to that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2026
First posted
May 22, 2026
StartActual
Oct 30, 2026was Sep 2026
Primary completionEst.
Jul 31, 2031
CompletionEst.
Jul 31, 2031
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 4, 2026
Sites
Vanderbilt University Medical Center is now Recruiting
Nov 4, 2026
Start date
Sep 2026→Oct 30, 2026 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Not yet recruiting→Recruiting
    Vanderbilt University Medical Center is now Recruiting
    Start date Sep 2026→Oct 30, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07602166
Responsible party
Annet Kirabo (Professor of Medicine Division of Clinical Pharmacology Department of Medicine, Vanderbilt University Medical Center) — Principal investigator
First posted
May 22, 2026
Start date
Oct 30, 2026
Primary completion
Jul 31, 2031 (estimated)
Completion
Jul 31, 2031 (estimated)
Last update
Nov 4, 2026

Study contacts

Annet Kirabo, D.V.M., M.Sc., Ph.D. F.A.H.A.
Contact
annet.kirabo@vumc.org
615-343-0933
Cindy Mambungu, LPN
Contact
cindy.a.booker@vumc.org
615-343-5828

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 2-(AMINOMETHYL)PHENOL

Start the discussion